Glp1
India-EU trade deal likely to help GLP-1 therapies become cheaper
India-EU FTA to lower tariffs on pharma, potentially making GLP-1 therapies like semaglutide cheaper and boosting adoption among diabetics in India
 "India-EU trade deal likely to help GLP-1 therapies become cheaper")
Gene therapy for weight loss: Can one shot replace lifelong GLP-1 drugs?
US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that aims to trigger long-term weight loss by programming the pancreas to produce more GLP-1 hormone
 "Gene therapy for weight loss: Can one shot replace lifelong GLP-1 drugs?")
GLP-1 drugs and pregnancy: Why stopping may trigger hidden risks
As GLP-1 use rises, research and experts warn the post-drug phase may be a critical window for weight gain, metabolic instability and unexpected pregnancies
 "GLP-1 drugs and pregnancy: Why stopping may trigger hidden risks")
Weight regain after weight loss drugs is common; here's how to prevent it
Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term
 "Weight regain after weight loss drugs is common; here's how to prevent it")
Why weight returns fast after stopping obesity drugs? Homeostasis explained
Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected
 "Why weight returns fast after stopping obesity drugs? Homeostasis explained")
Stopping Ozempic or Mounjaro? The weight may come back faster than you think
New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken
 "Stopping Ozempic or Mounjaro? The weight may come back faster than you think")
How 2025 marked a turning point for health science and innovation
From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine
 "How 2025 marked a turning point for health science and innovation")
From fibremaxxing to GLP-1s: What were India's top health trends in 2025?
From fibremaxxing and longevity clinics to GLP-1 drugs, AI hospitals and workplace mental health, 2025 reshaped how India talks about prevention, ageing and wellbeing
 "From fibremaxxing to GLP-1s: What were India's top health trends in 2025?")
Emcure targets pan-India obesity market with Poviztra semaglutide
As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities
 "Emcure targets pan-India obesity market with Poviztra semaglutide")
Mounjaro and the brain: Why cravings fade at first, then return later
A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect
 "Mounjaro and the brain: Why cravings fade at first, then return later")
GLP-1 weight-loss drugs likely to see value growth slowing down
Entry of generics post March 2026, patient dropouts to affect sales values, say experts
 "GLP-1 weight-loss drugs likely to see value growth slowing down")
Ozempic in India: What it does and how it fits into a growing health crisis
From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions
 "Ozempic in India: What it does and how it fits into a growing health crisis")
Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles
Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies
 "Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles")